Inappropriate platelet aggregation creates a cardiovascular risk that is largely managed with thienopyridines and aspirin. Although effective, these drugs carry risks of increased bleeding and drug ‘resistance’, underpinning a drive for new antiplatelet agents. To discover such drugs, one strategy is to identify a suitable druggable target and then find small molecules that modulate it. A good and unexploited target is the platelet collagen receptor, GPVI, which promotes thrombus formation. To identify inhibitors of GPVI that are safe and bioavailable, we docked a FDA-approved drug library into the GPVI collagen-binding site in silico. We now report that losartan and cinanserin inhibit GPVI-mediated platelet activation in a selective, competitive and dose-dependent manner. This mechanism of action likely underpins the cardioprotective effects of losartan that could not be ascribed to its antihypertensive effects. We have, therefore, identified small molecule inhibitors of GPVI-mediated platelet activation, and also demonstrated the utility of structure-based repurposing.
References
[1]
BHF (2009–2010) BHF coronary heart disease statistics. British Heart Foundation Health Promotion Research Group.
[2]
Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, et al. (2012) Heart disease and stroke statistics –2012 update: a report from the American Heart Association. Circulation 125: e2–e220. doi: 10.1161/cir.0b013e31823ac046
[3]
Yeung J, Holinstat M (2012) Newer agents in antiplatelet therapy: a review. J Blood Med 3: 33–42. doi: 10.2147/jbm.s25421
[4]
Michelson AD (2010) Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 9: 154–169. doi: 10.1038/nrd2957
[5]
Franchini M, Mannucci PM (2009) New antiplatelet agents: why they are needed. European journal of internal medicine 20: 733–738. doi: 10.1016/j.ejim.2009.09.005
[6]
Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673–683. doi: 10.1038/nrd1468
[7]
Mizushima T (2011) Drug discovery and development focusing on existing medicines: drug re-profiling strategy. J Biochem 149: 499–505. doi: 10.1093/jb/mvr032
[8]
NIH (2012) Rescuing and Repurposing Drugs. National Institutes of Health.
[9]
Huang R, Southall N, Wang Y, Yasgar A, Shinn P, et al. (2011) The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med 3: 80ps16. doi: 10.1126/scitranslmed.3001862
[10]
Ballester PJ, Mangold M, Howard NI, Robinson RL, Abell C, et al. (2012) Hierarchical virtual screening for the discovery of new molecular scaffolds in antibacterial hit identification. J R Soc Interface. doi: 10.1098/rsif.2012.0569
[11]
Katritch V, Jaakola VP, Lane JR, Lin J, Ijzerman AP, et al. (2010) Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem 53: 1799–1809. doi: 10.1021/jm901647p
[12]
Shoichet BK (2004) Virtual screening of chemical libraries. Nature 432: 862–865. doi: 10.1038/nature03197
[13]
Stoll G, Kleinschnitz C, Nieswandt B (2008) Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood 112: 3555–3562. doi: 10.1182/blood-2008-04-144758
[14]
Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, et al. (2007) Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 115: 2323–2330. doi: 10.1161/circulationaha.107.691279
[15]
Gibbins JM (2004) Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci 117: 3415–3425. doi: 10.1242/jcs.01325
[16]
Pugh N, Simpson AM, Smethurst PA, de Groot PG, Raynal N, et al. (2010) Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood. Blood 115: 5069–5079. doi: 10.1182/blood-2010-01-260778
[17]
Ungerer M, Rosport K, Bultmann A, Piechatzek R, Uhland K, et al. (2011) Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 123: 1891–1899. doi: 10.1161/circulationaha.110.980623
[18]
Goebel S, Li Z, Vogelmann J, Holthoff HP, Degen H, et al. (2013) The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke. PLoS One 8: e66960. doi: 10.1371/journal.pone.0066960
[19]
Muzard J, Bouabdelli M, Zahid M, Ollivier V, Lacapere JJ, et al. (2009) Design and humanization of a murine scFv that blocks human platelet glycoprotein VI in vitro. Febs J 276: 4207–4222. doi: 10.1111/j.1742-4658.2009.07129.x
[20]
Al-Tamimi M, Tan CW, Qiao J, Pennings GJ, Javadzadegan A, et al. (2012) Pathologic shear triggers shedding of vascular receptors: a novel mechanism for down-regulation of platelet glycoprotein VI in stenosed coronary vessels. Blood 119: 4311–4320. doi: 10.1182/blood-2011-10-386607
[21]
Horii K, Kahn ML, Herr AB (2006) Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. Blood 108: 936–942. doi: 10.1182/blood-2006-01-010215
[22]
Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, et al. (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66: 12–21. doi: 10.1107/s0907444909042073
[23]
McGann M (2011) FRED pose prediction and virtual screening accuracy. J Chem Inf Model 51: 578–596. doi: 10.1021/ci100436p
[24]
Bostrom J, Greenwood JR, Gottfries J (2003) Assessing the performance of OMEGA with respect to retrieving bioactive conformations. J Mol Graph Model 21: 449–462. doi: 10.1016/s1093-3263(02)00204-8
[25]
Grynkiewicz G, Poenie M, Tsien RY (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties. The Journal of biological chemistry 260: 3440–3450.
[26]
O'Connor MN, Smethurst PA, Farndale RW, Ouwehand WH (2006) Gain- and loss-of-function mutants confirm the importance of apical residues to the primary interaction of human glycoprotein VI with collagen. J Thromb Haemost 4: 869–873. doi: 10.1111/j.1538-7836.2005.01764.x
[27]
Smethurst PA, Joutsi-Korhonen L, O'Connor MN, Wilson E, Jennings NS, et al. (2004) Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody. Blood 103: 903–911. doi: 10.1182/blood-2003-01-0308
[28]
Ono K, Ueda H, Yoshizawa Y, Akazawa D, Tanimura R, et al. (2010) Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan (DuP-753) via glycoprotein VI. J Med Chem 53: 2087–2093. doi: 10.1021/jm901534d
[29]
Grothusen C, Umbreen S, Konrad I, Stellos K, Schulz C, et al. (2007) EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis. Arterioscler Thromb Vasc Biol 27: 1184–1190. doi: 10.1161/atvbaha.106.138693
[30]
Murad JP, Espinosa EV, Ting HJ, Khasawneh FT (2011) Characterization of the In Vivo Antiplatelet Activity of the Antihypertensive Agent Losartan. J Cardiovasc Pharmacol Ther. doi: 10.1177/1074248411425491
[31]
Gibbins JM, Okuma M, Farndale R, Barnes M, Watson SP (1997) Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. Febs Letters 413: 255–259. doi: 10.1016/s0014-5793(97)00926-5
[32]
Poole A, Gibbins JM, Turner M, van Vugt MJ, van de Winkel JG, et al. (1997) The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 16: 2333–2341. doi: 10.1093/emboj/16.9.2333
[33]
Murad JP, Espinosa EV, Ting HJ, Khasawneh FT (2012) Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan. J Cardiovasc Pharmacol Ther 17: 308–314. doi: 10.1177/1074248411425491
[34]
Guerra JI, Monton M, Rodriguez-Feo JA, Farre J, Jimenez AM, et al. (2000) [Effect of losartan on human platelet activation by thromboxane A2]. Rev Esp Cardiol 53: 525–530. doi: 10.1016/s0300-8932(00)75123-2
[35]
Shoichet BK (2006) Screening in a spirit haunted world. Drug Discov Today 11: 607–615. doi: 10.1016/j.drudis.2006.05.014
[36]
Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, et al. (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363: 2022–2031. doi: 10.1016/s0140-6736(04)16451-9
[37]
Feher G, Feher A, Pusch G, Lupkovics G, Szapary L, et al. (2009) The genetics of antiplatelet drug resistance. Clin Genet 75: 1–18. doi: 10.1111/j.1399-0004.2008.01105.x
[38]
Maree AO, Curtin RJ, Chubb A, Dolan C, Cox D, et al. (2005) Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 3: 2340–2345. doi: 10.1111/j.1538-7836.2005.01555.x
[39]
Lepantalo A, Mikkelsson J, Resendiz JC, Viiri L, Backman JT, et al. (2006) Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 95: 253–259. doi: 10.1160/th05-07-0516
[40]
Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, et al. (2009) Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 30: 1744–1752. doi: 10.1093/eurheartj/ehp157
[41]
O'Donnell CJ, Larson MG, Feng D, Sutherland PA, Lindpaintner K, et al. (2001) Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 103: 3051–3056. doi: 10.1161/01.cir.103.25.3051
[42]
Massberg S, Konrad I, Bultmann A, Schulz C, Munch G, et al. (2004) Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. Faseb J 18: 397–399. doi: 10.1096/fj.03-0464fje
[43]
Chen L, Gui C, Luo X, Yang Q, Gunther S, et al. (2005) Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. Journal of virology 79: 7095–7103. doi: 10.1128/jvi.79.11.7095-7103.2005
[44]
Yang Q, Chen L, He X, Gao Z, Shen X, et al. (2008) Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors. Chemical & pharmaceutical bulletin 56: 1400–1405. doi: 10.1248/cpb.56.1400
[45]
Bal Dit Sollier C, Crassard I, Simoneau G, Bergmann JF, Bousser MG, et al. (2009) Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovascular diseases 28: 505–513. doi: 10.1159/000236915
[46]
Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, et al. (2011) Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 377: 2013–2022. doi: 10.1016/s0140-6736(11)60600-4
[47]
Belhassen L, Pelle G, Dubois-Rande JL, Adnot S (2003) Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. Journal of the American College of Cardiology 41: 1198–1204. doi: 10.1016/s0735-1097(03)00048-2
[48]
Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, et al. (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 1004–1010. doi: 10.1016/s0140-6736(02)08090-x
[49]
Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, et al. (2002) Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. Jama 288: 1491–1498. doi: 10.1001/jama.288.12.1491
[50]
Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, et al. (2009) Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374: 1840–1848. doi: 10.1016/s0140-6736(09)61913-9
[51]
Kehoe PG, Passmore PA (2012) The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis? J Alzheimers Dis 30 Suppl 2S251–268.
